StockData
Immuron Ltd logo

Immuron Ltd (IMRN) stock

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30
$0.87−0.00 (-0.52%)

Close on Nov 18, 2026Market cap $6.99MP/E –Yield –

Immuron operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was -A$3.85M. The highest annual figure on record is -A$2.87M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-A$3.85M–
FY2025Jun 30, 2025-A$5.34M–
FY2024Jun 30, 2024-A$5.80M–
FY2023Jun 30, 2023-A$3.57M–
FY2022Jun 30, 2022-A$2.87M–
FY2021Jun 30, 2021-A$8.38M–
FY2020Jun 30, 2020-A$2.91M–
FY2019Jun 30, 2019-A$4.66M–
FY2018Jun 30, 2018-A$3.05M–
FY2017Jun 30, 2017-A$6.72M–

More Immuron figures

See a number that looks wrong?